



FILE NO. A32759 070165.0555  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Wilson et al.

Serial No. : 09/478,737

Examiner: Murphy, J.

Filed : January 6, 2000

Group Art Unit: 1646

For : SCREENING METHODS FOR COMPOUNDS  
USEFUL IN THE REGULATION OF  
POLYCYSTIC KIDNEY DISEASE

4/a  
J.G.J.  
6/6/01

RESPONSE TO RESTRICTION REQUIREMENT AND  
SUBMISSION OF SEQUENCE LISTING

I hereby certify that this paper is being deposited with the United States  
Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231

May 25, 2001  
Date of Deposit

Carmella L. Stephens  
Attorney Name

41,328  
PTO Registration No.

Carmella L. Stephens  
Signature

May 25, 2001  
Date of Signature

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement dated March 27, 2001,  
Applicants elect, with traverse, to pursue the invention of Group I, namely Claims 1-10,  
in the instant application. Applicants request that non-elected Claims 11-20 be canceled  
without prejudice to the prosecution of the subject matter of non-elected claims in other  
patent applications. Together with this Response, Applicants also enclose a Petition for

Extension of Time for One Month (37 CFR 1.136(a)), up to and including May 27, 2001.

The extension fee of \$110.00 is enclosed.

Further, also in response to to the Office Action of March 27, 2001,  
pursuant to 37 C.F.R. § 1.821-1.825, respectively, Applicants submit herewith a  
~~Sequence Listing in paper and computer readable form. I hereby state that the content of~~  
the paper and computer readable copies of the Sequence Listing submitted in accordance  
with 37 C.F.R. § 1.821(c) and (e), respectively, are the same. A copy of the Notice to  
Comply is attached. If any fees are associated with submission of the Sequence Listing,  
please charge Deposit Account No. 02-4377. Two copies of this sheet are enclosed.

Respectfully submitted,

Carmella L. Stephens

Richard S. Clark  
Patent Office Reg. No. 26,154  
Attorney for Applicant

Carmella L. Stephens  
Patent Office Reg. No. 41,328  
Agent for Applicant

Baker Botts L.L.P.  
30 Rockefeller Plaza  
New York, NY 10112

(212) 408-2539



Application No.: 09,487

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**